Pfizer is undervalued as markets fixate on its patent cliff, overlooking strong cash flows, pipeline upside, and a 7% yield.

RWE's risk/reward profile is less attractive after a 39% gain. Valuation is stretched with a rising P/E, low yield, and ...

Intercontinental Exchange is well-positioned for growth in FY25 with strong trading volumes, innovation and strategic M&A.

Varonis excels in data security with SaaS growth, but high valuation and unclear margins pose risks. Read here for an ...

Vanguard Short-Term Treasury Index Fund ETF Shares reduces portfolio risk, enhances liquidity, and stabilizes returns. Learn ...

Nike remains resilient amid tariffs, weak demand, and supply chain risks, supported by strong financials and brand value. See ...

VOOV provides defensive, value-driven exposure with lower tech weight, appealing amid inflation risks and slower growth. Find ...

Pampa Energía capitalizes on Argentina's stabilization, driving growth in LNG, shale oil and renewables. See more on PAM ...

Japan’s headline inflation moderated a bit to 3.5% YoY in May (vs 3.6% in April, 3.5% market consensus), in line with market ...

Five of the ten lowest-priced S&P 500 Dividend Aristocrats are currently attractive buys. Learn strategies for maximizing ...

Global private equity buyouts of corporate units (AKA carve-outs) have increased as corporations focus on balance sheets in ...

Palantir (PLTR) is a top investment in 2025, thriving on global instability with AI-powered defense solutions and robust ...